Literature DB >> 8141844

Familial lecithin:cholesterol acyltransferase deficiency: further resolution of lipoprotein particle heterogeneity in the low density interval.

M Guérin1, P J Dolphin, M J Chapman.   

Abstract

Patients presenting with a familial deficiency of lecithin:cholesterol acyltransferase (LCAT) typically exhibit multiple quantitative and qualitative perturbations of apo B- and apo A-I-containing plasma lipoproteins. Marked particle heterogeneity has been detected over the low-density range (d = 1.019-1.063 g/ml), involving lipoprotein(X) (LP-X) and large molecular weight LDL (LM-LDL). We describe the chromatographic fractionation and characterization of the major particle species distributed within the low-density interval in a new French LCAT-deficient family. Detailed analyses of the plasma lipoprotein and apolipoprotein spectrum are reported. The plasma lipoproteins were enriched in unesterified cholesterol and phospholipids with markedly reduced concentrations of cholesteryl esters. By a combination of gel filtration and affinity chromatography on heparin-sepharose, the heterogeneous mixture of low-density particles was resolved into three distinct particle populations: LP-X (diameter 400 A) corresponding to LM-LDL, an apo A-I and albumin-containing particle similar to LP-X2 (diameter 300 A), and cholesteryl ester-deficient (0.9%) triglyceride-rich (58.4%) LDL containing apo B-100 (diameter 260-270 A). Use of affinity chromatography allowed separation of HDL-like particles (diameter 140-160 A) which were rich in free cholesterol (21.4%) and phospholipids (52.9%) and which were isolated in association with LP-X upon gel filtration chromatography. Ultracentrifugal density gradient analysis of plasma from the LCAT-deficient subject over a period of 3 years showed a net shift of the lipoprotein distribution in the low density range due to an increase in plasma LP-X levels. We propose that the presence of LP-X in the plasma is correlated with a progressive alteration in the renal function recently observed in this patient.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8141844     DOI: 10.1016/0021-9150(93)90191-v

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Effect of lipoprotein-X on lipid metabolism in rat kidney.

Authors:  K O; M Ly; D Z Fang; J Frohlich; P C Choy
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  Immunochemical composition of cryoglobulins generated in stroke.

Authors:  Levon Manukyan; Anna Boyajyan; Arsen Arakelyan; Violetta Ayvazyan; Elina Arakelova; Robert Sim; George Grigoryan
Journal:  J Clin Immunol       Date:  2008-11-04       Impact factor: 8.317

3.  A case of acquired lecithin:cholesterol acyltransferase deficiency with sarcoidosis that remitted spontaneously.

Authors:  Tanino Akiko; Takafumi Okura; Tomoaki Nagao; Masayoshi Kukida; Daijiro Enomoto; Ken-Ichi Miyoshi; Jitsuo Higaki; Masayuki Kuroda; Hideaki Bujo
Journal:  CEN Case Rep       Date:  2016-06-07

4.  Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse.

Authors:  R P Elferink; R Ottenhoff; J van Marle; C M Frijters; A J Smith; A K Groen
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

5.  Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations.

Authors:  Akihiro Katayama; Jun Wada; Hitomi Usui Kataoka; Hiroko Yamasaki; Sanae Teshigawara; Takahiro Terami; Kentaro Inoue; Motoko Kanzaki; Kazutoshi Murakami; Atsuko Nakatsuka; Hitoshi Sugiyama; Norio Koide; Hideaki Bujo; Hirofumi Makino
Journal:  NDT Plus       Date:  2011-07-26

Review 6.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.